Send Message
801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsOral Medications

Amlodipine Besylate Tablets 2.5mg, 5mg, 10mg Oral Medications

Amlodipine Besylate Tablets 2.5mg, 5mg, 10mg Oral Medications

  • Amlodipine Besylate Tablets 2.5mg, 5mg, 10mg Oral Medications
Amlodipine Besylate Tablets 2.5mg, 5mg, 10mg Oral Medications
Product Details:
Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 2.5mg, 5mg, 10mg
Payment & Shipping Terms:
Minimum Order Quantity: 500, 000 tablets
Price: Negotiation
Packaging Details: 10’s/blister
Delivery Time: 45days
Payment Terms: T/T, L/C
Supply Ability: one million pills per day
Contact Now
Detailed Product Description
Product: Amlodipine Besylate Tablets Specification: 2.5mg, 5mg, 10mg
Standard: USP Packing: 10’s/blister
High Light:

oral treatment

,

oral preparation

Amlodipine Besylate Tablets 2.5mg, 5mg, 10mg Oral Medications

 

Product : Amlodipine Besylate Tablets

Specification : 2.5mg, 5mg, 10mg

Standard : USP

Packing : 10’s/blister

 

Description :

Amlodipine is a long-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, amlodipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Some studies have shown that amlodipine also exerts inhibitory effects on voltage-gated N-type calcium channels. N-type calcium channels located in the central nervous system may be involved in nociceptive signaling and pain sensation. Amlodipine is used to treat hypertension and chronic stable angina.

 

Indication

For the treatment of hypertension and chronic stable angina.

 

Pharmacodynamics

Amlodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that DHP CCBs target L-type calcium channels, the major channel in muscle cells that mediate contraction; however, some studies have indicated that amlodipine also binds to and inhibits N-type calcium channels (see references in Targets section). Similar to other DHP CCBs, amlodipine binds directly to inactive L-type calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives amlodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, amlodipine has little effect on cardiac myocytes and conduction cells.

 

Mechanism of action

Amlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of amlodipine result in an overall decrease in blood pressure. Amlodipine is a long-acting CCB that may be used to treat mild to moderate essential hypertension and exertion-related angina (chronic stable angina). Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase I activity causing cellular pH increases which may be involved in regulating intracelluar calcium influx through calcium channels.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Mr. Luke Liu

Tel: 86--57487019333

Fax: 86-574-8701-9298

Send your inquiry directly to us (0 / 3000)

Other Products